Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093895 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis
A Phase 2 study, sponsored by Geistlich Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04093895 is a Phase 2 study that has completed, run by Geistlich Pharma. The registered enrollment target is 12 participants.
The verdict
NCT04093895, a Phase 2 study, has completed, sponsored by Geistlich Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
A Phase 2, uncontrolled, open-label, single arm study to evaluate the safety, tolerability and efficacy of PerioSept® (3%) as adjunct to Scaling and Root Planing in subjects with periodontitis.
Interventions
- DRUG PerioSept(r)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2020-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04093895
The ClinicalTrials.gov registry entry for NCT04093895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geistlich Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PerioSept(r) is the first listed.
NCT04093895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04093895 about?
NCT04093895 is a clinical study titled "Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis". A Phase 2, uncontrolled, open-label, single arm study to evaluate the safety, tolerability and efficacy of PerioSept® (3%) as adjunct to Scaling and Root Planing in subjects with periodontitis.
What is the current status of trial NCT04093895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-08-26. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT04093895?
The interventions under investigation include: PerioSept(r) (DRUG).
Who is sponsoring clinical trial NCT04093895?
This trial is sponsored by Geistlich Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.